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We report the ﬁrst case of oseltamivir-induced pneumonia. A 50-year-old man was
diagnosed with inﬂuenza and prescribed oseltamivir. He had a persistent high fever, and
developed a productive cough with peripheral blood eosinophilia and his chest radiograph
showed ground glass opacity. Bronchoalveolar lavage ﬂuid and histological ﬁndings
obtained from transbronchial lung biopsy suggested eosinophilic pneumonia with
component of cryptogenic organizing pneumonia. Drug lymphocyte stimulation test
against oseltamivir was positive. In spite of discontinuation of oseltamivir, his condition did
not ameliorate. He was treated with prednisolone for oseltamivir-induced lung injury and
the symptoms improved immediately. We should recognize oseltamivir-induced pneumonia
as a differential diagnosis in the case of developing pneumonia following treatment with
oseltamivir.
& 2008 Elsevier Ltd. All rights reserved.Introduction
The numbers of drugs causing lung injury are rapidly
increasing. Drug-induced lung injury can be serious and
even fatal without quick discontinuance of the causative
drugs and the adoption of appropriate measures.1,2 How-
ever, the diagnosis of drug-induced lung injury is veryElsevier Ltd. All rights reserved.
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rume-u.ac.jp (Y. Iwata).difﬁcult, because the clinical, radiographic, and pathologi-
cal features are nonspeciﬁc. Moreover there are no speciﬁc
tests for diagnosing drug-induced lung injury. Oseltamivir is
administered for inﬂuenza infection and is stockpiled as a
measure against the occurrence of an inﬂuenza pandemic.
No serious adverse effects induced by oseltamivir have been
reported.
Case report
A 50-year-old man consulted a neighboring doctor because
of a sudden high fever (38.2 1C), sore throat, and arthralgia.
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Figure 2 Histological ﬁndings showing ﬁbrinous exudate
containing macrophages and eosinophilis, and organization in
the alveolar space (used hematoxylin and eosin stain, original
2-1 200, 2-2 400).
Y. Iwata et al.134He had been healthy until then. Although his point-of-care
rapid inﬂuenza test was negative, he was diagnosed as
having inﬂuenza because his daughter who lives with him
was diagnosed as having inﬂuenza A infection almost at the
same time by a rapid inﬂuenza test (ESPLINEs Inﬂuenza
A&B-N, FUJIREBIO Inc., Tokyo) and his symptoms were
identiﬁable with acute inﬂuenza infection. It was more
possible that his negative rapid inﬂuenza test was examined
too early or not adequately. He was prescribed oseltamivir
(150mg/day) and he took it for 5 days. He took acetami-
nophen 500mg only once as antipyretics/analgesics on the
ﬁrst day. A high fever of near 39 1C persisted and he
developed a productive cough. On Day 6 he consulted the
doctor again. Abnormal shadow had not been detected in
the chest radiograph when he caught a cold before. A chest
radiograph showed ground glass opacity all over the left
lung. The white blood cell (WBC) count was 8700/ml, with
68% neutrophilis and 10.0% eosinophilis (870/ml). C-reactive
protein (CRP) was 9.1 g/dl. On Day 9 he was referred to our
hospital with progressive exertional dyspnea despite the
commencement of antibiotics (azithromycin (AZM) 500mg/day
and ceftriaxone sodium (CTRX) 1 g/day) for 3 days under
suspicion of secondary bacterial pneumonia. He was a
farmer but was not using any pesticides at that time. He
also denied any other signiﬁcant exposure or treatment with
medications. He had no past history of allergies and had
never smoked. There were no symptoms or examination
results suggestive of underlying connective tissue disease.
On physical examination, ﬁne inspiratory crackles were
noted over the left lung ﬁelds. Peripheral blood eosinophilia
(723/ml) was prolonged with the elevation of CRP (14.2mg/dl).
Renal and liver function tests were normal. Krebs von den
Lungen-6(KL-6) (377U/ml) was also normal. Arterial blood
gas analysis revealed slight hypoxemia (pH 7.441, PaO2
9.99 kPa, PaCO2 5.28 kPa in room air). Ground glass opacity
shown on the chest radiograph was deteriorated. High-
resolution computed tomography (HRCT) demonstrated
patchy areas of air space consolidation and ground glass
attenuation, dominantly in the peripheral zone of the left
lung (Figure 1). The opacity in the right lung was very subtle.
Treatment with antibiotics was stopped. On Day 10 (the day
after admission), bronchoalveolar lavage (BAL) was per-
formed through left bronchus (B4a) with 60% recovery. BAL
ﬂuid disclosed an increased total cell count (134 104/ml),Figure 1 High-resolution computed tomography scan showing patch
dominantly in peripheral zone of the left lung and the opacity in thwith 32.1% lymphocytes, 41.9% neutrophilis, 21.6% eosino-
philis, and 3.7% macrophages. The CD4/CD8 ratio of the BAL
ﬂuid lymphocytes was 2.51. The culture of BAL ﬂuid wasy areas of air space consolidation and ground glass attenuation,
e right lung was very subtle.
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Oseltamivir-induced pneumonia 135sterile. Histological ﬁndings obtained from transbronchial
lung biopsy (TBLB) were more likely those of eosionophilic
pneumonia pattern, showing ﬁbrinous exudate containing
macrophages and eosinophils, and organization in the
alveolar space (Figure 2). As drug-induced lung injury
was highly suspected, drug lymphocyte stimulation test
(DLST) was performed. The lymphocyte stimulation index
(SI) % was 234% by oseltamivir, 100% by AZM, and 94% by
CTRX (control 100%). Only oseltamivir was remarkably
positive. Taking the DLST result and his clinical course into
account, we concluded that the pneumonia was induced by
oseltamivir. Despite the withdrawal of oseltamivir, his
condition deteriorated. Hence, he was treated with pre-
dnisolone, initially at 45mg/day. His condition ameliorated
immediately. The prednisolone dose was tapered slowly and
discontinued over 1 month. He remained well without
relapse.Discussion
Administration of oseltamivir phosphate as its ethyl ester
prodrug is efﬁcacious in inﬂuenza A and B infection.
Oseltamivir is a potent inhibitor of inﬂuenza neuraminidase,
an enzyme important for inﬂuenza replication, in that it
facilitates the release of newly formed virus particles from
infected cells.3 Oseltamivir is generally well-tolerated,
although nausea and vomiting occur occasionally. No other
fatal adverse effects have been described.4–6 A case of
pneumonia suspected to be induced by oseltamivir was
reported in Japan.7 To our knowledge, no case of deﬁnitive
oseltamivir-induced pneumonia has been reported.
The diagnosis of drug-induced lung injury begins with
suspecting the occurrence. Any drug, herbal medicine, and
health food could cause lung injury. We should recognize
that drug-induced lung injury could occur not only under
administration but also after withdrawal.1,2 Drug-induced
pneumonia generally improves by discontinuation of the
drug. However, we need to be aware of cases that become
worse even after withdrawal. Diagnosis requires the
temporal association of the manifestation and the admini-
stration by detailed history taking, besides the meticulous
exclusion of other respiratory illness.8 Rechallenge test is a
conclusive measure with high risk, only if no alternate
therapy drug is available for treating the basic disease.2 In
addition, we need to know which pattern of lung injury the
drug could cause clinically, radiographically, and histopatho-
logically. Such data are available from the updated
Pneumotoxs website.9 At the time of admission, we
considered the possibility of inﬂuenza pneumonia, atypical
pneumonia, secondary bacterial pneumonia, and drug-
induced lung injury as differential diagnoses. TBLB and
BAL are usually useful for diagnosing whether there is
infection or not. We found no pathogenesis in these
specimens. Without treatment, the fever of people infected
with acute inﬂuenza commonly resolves within 3 or 4 days
and is cured in 1 week. Administration of oseltamivir
reduces the duration of illness.4,5 Inﬂuenza pneumonia was
unlikely because he was healthy and took oseltamivir. The
appearance of peripheral blood eosinophilia and pneumonia
on Day 6 was suggestive of drug-induced lung injury.
Acetaminophen was unlikely to be a causative agentbecause he received this medication only once. At this
point we were able to strongly suspect oseltamivir-induced
lung injury in the context of his clinical course. There was
little likelihood that AZM and CTRX were offensive drugs
because of their commencement after the occurrence of the
pneumonia.
DLST is the proliferation test to detect a T-cell sensitiza-
tion to drugs, which measures 3H-thymidine uptake of
dividing cells, induced by delay allergy. The test has not
been well-established, and its usefulness has been demon-
strated in the last year.10 Nevertheless, a positive DLST is
often a valuable contribution of drug allergy.10 A positive
test against only one drug within three candidate drugs is
surely helpful to pinpoint the relevant drug, like this case.
But, as the sensitivity of DLST is limited, a negative DLST
cannot exclude a drug hypersensitivity.10 DLST may be
helpful and adjunctive if drug-induced lung injury is
suspected.
Mechanisms of drug-related lung pneumonitis are classi-
ﬁed as immunological or toxicological.11,12 Allergic types
show good response to corticosteroid therapy. The present
case shows an eosinophilia in peripheral blood and BAL ﬂuid,
a pathological feature of eosinophilic pneumonia and
positive result of DLST. All these features suggest that this
case was an allergic type. His image was compatible with
cryptogenic organizing pneumonia (COP), that is nonseg-
mental consolidation and ground-glass opacities most
commonly involving mainly the peripheral lung region,
except for atypical of the extreme asymmetry.13 However,
it is difﬁcult to differentiate between COP and eosinophilic
pneumonia.14 A large number of drug-induced lung injury
HRCT are usually of limited value in determining the
pathological pattern and prognosis.15 One drug could induce
several patterns simultaneously.16 This case contains the
character of eosionophilic pneumonia and COP. Histological
ﬁndings were more likely eosionophilic pneumonia pattern,
with eosinophilia of BAL and peripheral blood. The ﬁndings
of BAL were more likely COP rather than eosionophilic
pneumonia for reason that the eosinophil count in the BAL
was much lower than neutrophil (typically BAL eosinophilia
more than 25–30% in eosionophilic pneumonia patients17).
The BAL pattern in COP is characterized by colorful cell
differentials with an increase in all cell types, most
markedly in lymphocytes and more moderately in neutro-
phils and eosinophils.18 In spite of withdrawal of the
causative drug, many cases of drug-induced lung injury
worsen and require corticosteroid therapy, and moreover
slower tapering of corticosteroid is needed due to the risk of
relapse.2
It is highlighted the Japanese more frequently develop
drug-induced lung injury than Westerners. A large number of
drug-induced pulmonary diseases have been reported from
Japan. The incidences of fatal drug-induced lung pneumonia
by bleomycin, geﬁtinib, and inﬂiximab are remarkably
higher in Japan than those in other countries.19,20 This is
probably related with ethnic differences.Conﬂict of interest statement
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